| |
sham + vehicle
|
sham + dapa
|
sham + T-1095
|
MI + vehicle
|
MI + dapa
|
MI + T-1095
|
|---|
|
N
|
5
|
6
|
4
|
20
|
13
|
13
|
|
EDP (mmHg)
|
11 ± 2
|
12 ± 1
|
16 ± 2*
|
18 ± 1*
|
19 ± 1*‡
|
26 ± 2*†
|
|
Pes (mmHg)
|
117 ± 11
|
127 ± 7
|
127 ± 15
|
107 ± 5
|
105 ± 5
|
95 ± 5*
|
|
HR (bpm)
|
296 ± 12
|
288 ± 12
|
299 ± 11
|
270 ± 7*
|
258 ± 6*
|
260 ± 9*
|
|
dP/dtmax (mmHg/s)
|
7031 ± 426
|
7471 ± 514
|
7815 ± 504
|
5443 ± 305*
|
5141 ± 249*
|
4201 ± 264*†‡
|
|
dP/dtmin (mmHg/s)
|
− 7190 ± 631
|
− 7922 ± 637
|
− 8927 ± 906*
|
− 4318 ± 260*
|
− 4192 ± 224*
|
− 3290 ± 246*†‡
|
|
EDPVR (mmHg/ml)
|
0.024 ± 0.004
|
0.025 ± 0.002
|
0.03 ± 0.01
|
0.06 ± 0.01
|
0.05 ± 0.01
|
0.10 ± 0.02*†‡
|
|
Tau (ms)
|
12.5 ± 0.6
|
12.6 ± 0.8
|
12.5 ± 0.7
|
17.5 ± 0.6*
|
18.0 ± 0.5*
|
23.2 ± 1.6*†‡
|
- EDP end-diastolic pressure, Pes end-systolic pressure, HR heart rate, EDPVR end-diastolic pressure volume relationship, ESPVR end-systolic pressure volume relationship
- * p < 0.05 vs. sham + vehicle group; † p < 0.05 vs. MI + vehicle group; ‡ p < 0.05 vs. MI + dapagliflozin group
